Affordable Access

Publisher Website

Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy. A randomized, controlled trial

Authors
Publisher
Elsevier B.V.
Volume
4
Issue
1
Identifiers
DOI: 10.1016/j.preghy.2013.08.001
Keywords
  • Severe Hypertensive Disorders Of Pregnancy
  • Hypertensive Crisis
  • Persistent Hypertension
  • Hydralazine
  • Labetalol

Abstract

Synopsis Hydralazine and labetalol for intravenous use are equally effective in the management of hypertensive crisis in pregnant patients (24weeks or more) with severe hypertensive disorders of pregnancy, showing a similar frequency of adverse effects in both groups.

There are no comments yet on this publication. Be the first to share your thoughts.